VivoSeq
Other

Baricitinib

0

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Baricitinib is an early-stage landscape with 0 programs across 1 company. The most active players are Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Completed14 · 64%
Unknown status2 · 9%
Recruiting2 · 9%
Terminated2 · 9%
Not yet recruiting2 · 9%

Clinical Trials

Trial Activity

22 trials

Baricitinib for Reduction of HIV - CNS
Recruiting·—·Phase 2·NCT05452564·95 enrolled
Baricitinib in the Treatment of Intestinal Behçet's Syndrome
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06849908·56 enrolled
Baricitinib in CPPD - the BAPTIST Study
Not yet recruiting·—·Phase 2·NCT06768294·32 enrolled
Baricitinib Curative Repression of HIV-1
Not yet recruiting·EEmory University·Phase 2·NCT07209267·20 enrolled
A Study of Baricitinib and Rifampicin in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01910311·18 enrolled
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
Completed·UUniversity of Manchester·Phase 2·NCT04208464·15 enrolled
A Study of Baricitinib and Probenecid in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01937026·18 enrolled
A Study of Baricitinib and Omeprazole in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01925144·30 enrolled
A Study of LY3009104(Baricitinib) for Healthy Subjects
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01247350·34 enrolled
A Study of Baricitinib and Birth Control Pills in Healthy Females
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01896726·20 enrolled
A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT02340104·8 enrolled
A Study of Baricitinib and Simvastatin in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01960140·40 enrolled
A Study of Baricitinib and Ciclosporin in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01968057·18 enrolled
A Study of Baricitinib in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT03212638·42 enrolled
A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01924299·36 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)